3don MSN
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More
The drugmaker should significantly mitigate its most important risk as it develops new products.
A label can end a debate before the evidence is heard. From Nazi propaganda to "quack" science, see how labels are weaponized ...
Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX ...
Centessa Pharmaceuticals brings a fresh scheduled quarterly reporting event today into focus as readers assess program prioritization, study execution, scientific validation, and cash runway. Centessa ...
Citius Pharmaceuticals (NASDAQ:CTXR) is in focus as clinical focus meets a fresh company-specific catalyst. The article ...
KFF Health News on MSN
Newsom promotes affordable insulin, but California’s generic label off to a slow start
California is the first to launch state-branded insulin as Gov. Gavin Newsom tries to disrupt the pharmaceutical industry.
(OTC: NDTP), through its wholly owned subsidiary Good Salt Life, Inc., today announced a major expansion of the EPA-approved label for its flagship product, (EPA Reg. No. 96503-1-103745). The same ...
Q2 2026 Earnings Call August 13, 2026 4:30 PM EDTCompany ParticipantsDavid Krempa - Chief Business OfficerSean ...
Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025Q2 2026 fully diluted GAAP EPS of $0.35, ...
Guidance for Q3 2026 estimates an operational net cash burn of $18 million as the company ramps up commercial workstreams.
Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results